Results 11 to 20 of about 41,299 (161)
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
Frontiers in Neurology, 2022 The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and ...
Gregory D. Scott +54 more
doaj +1 more source
False memories in Lewy‐body disease [PDF]
Scandinavian Journal of Psychology, 2015 Recently, de Boysson, Belleville, Phillips et al. (2011) found that patients with Lewy‐body disease (LBD) showed significantly lower rates of false memories than healthy controls, using the Deese–Roediger–McDermott (DRM) experimental procedure. Given that this result could be explained by the practically null rate of true recognition in the LBD group ...
Salvador Algarabel +4 more
openaire +3 more sources
Alzheimer’s Research & Therapy, 2022 Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice.
John T. O’Brien +5 more
doaj +1 more source
Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study
Journal of Parkinson’s Disease, 2022 Background: Prodromal multiple system atrophy (MSA) has been characterized mainly by retrospective chart reviews. Direct observation and tracking of prodromal markers in MSA have been very limited Objective: To report the baseline characteristics and ...
Ronald B. Postuma +3 more
doaj +1 more source
A new visual rating scale for Ioflupane imaging in Lewy body disease
NeuroImage: Clinical, 2018 Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy ...
Jim J. Lloyd +7 more
doaj +1 more source
Journal of the Neurological Sciences, 2019 Diffuse Lewy body disease, also called dementia with Lewy bodies (DLB), is defined as progressive dementia and pathological Lewy bodies distributed in the central and autonomic nervous systems. The clinical features are dementia, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD).
Yu Wei Lin, Daniel Truong
openaire +4 more sources
Cortical Lewy body disease [PDF]
Journal of Neurology, Neurosurgery & Psychiatry, 2004 Cortical Lewy body disease reflects the presence of cortical Lewy bodies but without a clear clinical correlation Cortical Lewy body disease is a pathological observation rather than a distinct clinicopathological entity. Cortical Lewy bodies (CLB) are typically found in Parkinson’s disease and dementia with Lewy bodies (DLB), although they may also ...
openaire +2 more sources
Journal of Parkinson’s Disease, 2016 Background: Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy.
Thomas G. Beach +17 more
doaj +1 more source
A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease
Acta Neuropathologica Communications, 2019 Lewy body diseases are neurodegenerative disorders characterized by Lewy bodies in the brain. Lewy body dementia (LBD) refers to two forms of Lewy body disease: Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB).
Benjamin R. Smith +6 more
doaj +1 more source
Parkin disease and the Lewy body conundrum
Movement Disorders, 2013 A clear pathologic hallmark like that identified in sporadic Parkinson’s disease (PD) is lacking in many of the monogenic causes of PD. In leucine-rich repeat kinase 2 (LRRK2) mutations (PARK8), alpha-synuclein pathology in the form of Lewy bodies (LBs) is frequently, but not consistently, observed. Other pathologies reported in LRRK2 cases include tau
Doherty, KM, Hardy, J
openaire +3 more sources